PPT-3D (Paritaprevir-Ritonavir-

Ombitasvir Dasabuvir RBV in GT1b PEARLII Phase 3 Treatment Experienced Andreone P et al Gastroenterology 201414735965 Source Andreone P et al Gastroenterology 201414735965. Paritaprevir. -. Ritonavir (. Technivie. ). Prepared by: . David H. Spach, MD. Last . Updated: . July 27, 2015. Background and Dosing. Ombitasvir-Paritaprevir. -. Ritonavir (. Technivie. ) . Ombitasvir-Paritaprevir. -Ritonavir. -Ombitasvir . + Dasabuvir) . + RBV in . GT1. SAPPHIRE-II. Phase . 3. Treatment. . Experienced. Zeuzem. S, . et al. N . Engl. J Med. . 2014;370:1604-14.. Source: . Zeuzem. S, et al. N . OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + RBV. Randomisation*. 1 : . 1. Open-label. 18-70 years. HCV genotype 1. HCV RNA ≥ 10,000 IU/ml. Naïve or pre-treated with PEG-IFN + RBV. HIV infection, on ATV/. SAPPHIRE-I. Phase 3. . Treatment. . Naïve. Feld JJ, et al. N . Engl. J Med. 2014;370:1594-1603.. Source: Feld JJ, et al. N . Engl. J Med. 2014;370:1594-1603.. 3D . (Paritaprevir-Ritonavir-. Ombitasvir + Dasabuvir) + Ribavirin in GT1. OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + RBV. Randomisation*. 1 : . 1. Open-label. 18-70 years. HCV genotype 1. HCV RNA ≥ 10,000 IU/ml. Naïve or pre-treated with PEG-IFN + RBV. HIV infection, on ATV/. . and Dasabuvir +/- . RBV in . GT1b. PEARL-II. Phase . 3. Treatment. . Experienced. Andreone. P, . et al. . Gastroenterology. 2014;147:359-65.. Source: . Andreone. P, et al. Gastroenterology. 2014;147:359-65.. Paritaprevir. -. Ritonavir. . and . Dasabuvir. +/- RBV in GT1. PEARL-III and PEARL-IV. Phase 3. . Treatment. . Naïve. Ferenci. P, et al. N . Engl. J Med. 2014;370:1983-92.. Source: . Ferenci. . -. Ritonavir . and Dasabuvir . + RBV in . GT1. SAPPHIRE-II. Phase . 3. Treatment. . Experienced. Zeuzem. S, . et al. N . Engl. J Med. . 2014;370:1604-14.. Source: . Zeuzem. S, et al. N . Engl. . and Dasabuvir + RBV in GT1. SAPPHIRE-I. Phase 3. . Treatment. . Naïve. Feld JJ, et al. N . Engl. J Med. 2014;370:1594-1603.. Source: Feld JJ, et al. N . Engl. J Med. 2014;370:1594-1603.. Ombitasvir-Paritaprevir-Ritonavir . Feld JJ. NEJM . 2014;370:1594-1603. SAPPHIRE-I . Study. : . o. mbitasvir/paritaprevir/ritonavir. . + . d. asabuvir. . + . ribavirin. . for genotype 1. Treatment regimens. Co-formulated . ombitasvir. . + Dasabuvir) + RBV in GT1 . TURQUOISE-I. Phase . 2 . Treatment. Naïve and Treatment . Experienced. Wyles. D, et al. 65. th. AASLD. 2014: Abstract . 1939. . . HIV Coinfection. Source: . Wyles. D, et al. 65. Updated: . July . 6. , . 2015. Treatment of Hepatitis C in Patients with Renal Insufficiency. Robert G. Gish MD. Professor Consultant, Stanford University Medical Center. Senior Medical Director, St Josephs Hospital and Medical Center, Liver Program, Phoenix, Arizona. DSV . placebo. Randomisation*. Partial blind. 18-70 years. Chronic HCV infection. Genotype 1 . Treatment-naïve. HCV RNA > 10,000 IU/ml. No cirrhosis. No HBV or HIV co-infection. * Randomisation 1:2 if genotype 1a (PEARL-IV) ; . Prepared by: . Sophie . Woolston. , MD and David H. Spach, MD. Last . Updated: . November 18, 2014. 3D. Background and Dosing. 3D (. Paritaprevir. -Ritonavir-. Ombitasvir. + . Dasabuvir. ). 3D (. Paritaprevir.